pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,874 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1220Endpoints923BioPharma Dive355BioSpace342Fierce Biotech325onclive165raps111globenewswire health
therapy area
allOncology8305Rare Disease1946Cardiology1880Immunology1591Hematology1354Pulmonology1298Vaccines
  • Alternative medicine often feels more personal than conventional care, says physician
    Dr. Hannah Kerman, a New York physician, writes that many patients turn to acupuncturists or massage therapists because they feel more attended to than during typical medical visits. She describes…
    STAT · 4mo agoNeutral↗ source
  • Pfizer settles with generics to extend tafamidis patent until 2031, protecting revenue
    Pfizer announced settlements with three generic manufacturers-Dexcel Pharma, Hikma Pharmaceuticals and Cipla-to delay the launch of generic versions of tafamidis, the active ingredient in its rare‑…
    BioPharma Dive · 4mo agoDealPositive↗ source
← prev
page 73 of 75
next →
73
fda recalls71
fda medwatch63
fda press38
1283
Psychiatry & CNS899
Ophthalmology521
Pain503
Endocrinology & Metabolism497
Infectious Disease461
  • Boehringer’s dual-acting obesity shot survodutide meets primary goal in Phase 3, showing strong weight loss and muscle-preserving effect
    Boehringer Ingelheim announced that its dual-acting injectable obesity therapy, survodutide, achieved its primary endpoint in a Phase 3 study. Participants receiving the drug lost significantly mo…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • FDA urges Amgen to withdraw Tavneos after alleging data manipulation by former developer
    The FDA has sent a formal letter to Amgen recommending that the company pull its drug Tavneos from the market. The agency says new information shows the original approval filings from ChemoCentryx…
    BioPharma Dive · 4mo agoRegulatoryNegative↗ source
  • Eli Lilly partners with AI startup Profluent to develop next-generation gene editors
    Eli Lilly announced a collaboration with AI-focused biotech Profluent to create advanced gene-editing tools that could insert whole genes into patients. The partnership is intended to move beyond…
    STAT · 4mo agoDealPositive↗ source
  • Novartis CEO says Trump’s drug pricing plan creates a very difficult situation for makers and patients
    Novartis chief executive Vas Narasimhan warned that the United States drug‑pricing policy under President Trump presents a "very difficult situation" for both drugmakers and patients. He said the…
    STAT · 4mo agoRegulatoryNegative↗ source
  • BridgeBio's heart drug Attruby exceeds sales expectations, shifting investor outlook
    BridgeBio prepared to sell its heart drug Attruby on its own, prompting skepticism from investors and analysts who doubted the company could compete with larger rivals. The drug far outperformed f…
    BioPharma Dive · 4mo agoPositive↗ source
  • AIDS advocacy group sues Trump administration over hidden Gilead HIV-prevention settlement
    The AIDS advocacy group PrEP4All filed a lawsuit against the Trump administration, alleging it failed to disclose a research and development agreement with Gilead Sciences. The agreement was part…
    STAT · 4mo agoRegulatoryNegative↗ source
  • FDA launches AI-driven pilot to review trial data in real time, aiming to speed clinical studies
    Washington officials said the Food and Drug Administration is starting a new program to speed clinical trials by reviewing data as it is generated. The first pilots will use real-time data from tr…
    STAT · 4mo agoRegulatoryPositive↗ source
  • FDA commissioner touts real-time trial monitoring to cut drug development dead time
    The Food and Drug Administration announced a new approach that will let regulators view clinical trial endpoints as they happen, using cloud‑based data streams. The move targets the long delays th…
    STAT · 4mo agoRegulatoryPositive↗ source
  • Supreme Court to Hear Arguments on “Skinny Labeling” Case Impacting Generic Drug Access
    The U.S. Supreme Court scheduled oral arguments for Wednesday on a case concerning “skinny labeling,” a practice used by generic drug makers. Skinny labeling involves seeking approval to market a…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Coultreon secures $125M Series A to advance oral immune drug into Phase 2 trials
    Coultreon Biopharma announced a $125 million Series A financing round to fund development of an oral drug it licensed from Galapagos. The round was led by Sofinnova Investments and included nine i…
    BioPharma Dive · 4mo agoDealPositive↗ source
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    STAT · 4mo agoDealNeutral↗ source
  • GOP Medicaid work requirements face data gap as states not required to report implementation
    The 2025 tax cut law added work requirements to Medicaid, prompting a sharp partisan split. Democrats warn the new rules will create red tape and lead to loss of coverage, while Republicans argue t…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Health system CEOs face Congress on affordability, hearing shifts blame to opposing party's policies
    The House Ways and Means Committee held a hearing to examine the drivers of rising health‑care costs, calling CEOs of several large health systems to testify. CEOs from HCA Healthcare, CommonSpiri…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Experts warn brain-health initiatives overlook mental illness
    The authors – a professor at Oxford and Yale, the dean of Mount Sinai’s medical school, and a former U.S. congressman – argue that the surge in funding for neuroscience is being directed mainly tow…
    STAT · 4mo agoNegative↗ source
  • Former NIAID adviser David Morens indicted for hiding emails and falsifying records
    David Morens, a former senior adviser at the National Institute of Allergy and Infectious Diseases, was indicted on Tuesday for allegedly concealing emails and providing false responses to Freedom…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Google’s clinical director discusses AI challenges in health care in STAT Health Tech newsletter
    STAT Health Tech newsletter featured an interview with Google’s clinical director, focusing on the practical challenges of deploying artificial intelligence in health care settings. The discussion…
    STAT · 4mo agoNeutral↗ source
  • New hepatitis B vaccine guidance prompts analysis of public trust and policy impacts
    The Morning Rounds newsletter examines how the latest recommendations for a hepatitis B vaccine could affect public health outcomes. It highlights recent surveys that show varying levels of confid…
    STAT · 4mo agoNeutral↗ source
  • EPA proposes first rule to flag microplastics and pharmaceuticals in drinking water, alongside $144 million ARPA-H study program
    The Environmental Protection Agency announced a proposed rule that would formally label microplastics and pharmaceutical residues in drinking water as contaminants that merit federal study and trac…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Google AI clinical director says chatbot can serve as bridge for mental health crises
    Google’s clinical director, Megan Jones Bell, told STAT that the company is working to make its Gemini chatbot a helpful resource for users experiencing mental health crises. She emphasized that th…
    STAT · 4mo agoPositive↗ source
  • STAT seeks reader input on adopting AP’s “healthcare” spelling
    The Associated Press Stylebook recently announced that the term "healthcare" should be written as a single word, updating its long-standing guidance. STAT, which has used the two-word form "health…
    STAT · 4mo agoNeutral↗ source
  • Intellia's single-dose CRISPR therapy cuts hereditary angioedema attacks in Phase 3 trial
    Intellia Therapeutics reported that its gene-editing candidate lonvo-z produced a dramatic reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 study. The single-dose…
    STAT · 4mo agoPositive readoutPositive↗ source
  • Intellia’s CRISPR therapy cuts hereditary angioedema attacks by 87% in Phase 3 trial
    Intellia Therapeutics reported that its experimental CRISPR-based drug lonvo-z met the primary endpoint in a Phase 3 study for hereditary angioedema, a rare swelling disorder. The trial showed an…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trial
    Intellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…
    STAT · 4mo agoPositive readoutPositive↗ source